Literature DB >> 9215785

Contrast-enhanced magnetization transfer imaging: improvement of brain tumor conspicuity and delineation for radiosurgical target volume definition.

H Hawighorst1, J Debus, W Schreiber, M V Knopp, R Engenhart-Cabillic, M Essig, G Brix, G van Kaick.   

Abstract

PURPOSE: To assess the contrast-noise-ratio (CNR), and thus tumor conspicuity and delineation, on contrast-enhanced T1-weighted magnetization transfer (MT) images compared to conventional T1-weighted spin echo (SE) images as a strategy to improve definition of the macroscopic boost volume in radiosurgery treatment planning in patients with high grade gliomas or metastatic brain lesions.
MATERIALS AND METHODS: Fifty patients (mean age, 51 years) with histologically proven or suspected high grade glioma or cerebral metastases were prospectively examined by MR imaging. Following gadolinium dimeglumine administration (0.1 mmol/kg body weight) the brain was imaged with both a T1-weighted MT-fast low angle shot (FLASH) pulse sequence and with a conventional T1-weighted SE sequence without MT saturation. Lesion conspicuity, size and CNR were compared for both techniques.
RESULTS: The mean tumor diameter of malignant gliomas was significantly (P < 0.01) larger when measured on T1-weighted MT-FLASH images compared to T1-weighted SE images and was comparable for metastatic lesions. The mean CNR of enhancing lesions on T1-weighted MT-FLASH was 14 +/- 5 compared to 10 +/- 4 on SE images, representing a significant (P < 0.05) improvement. Lesion conspicuity and delineation was improved in 10 of 20 patients (50%) with high grade gliomas and in 15 of 30 patients (50%) with metastases. Additional contrast enhancing lesions were detected in 8 of 30 patients (27%) with metastases on MT-FLASH images. Lesion conspicuity was markedly improved in the posterior fossa. DISCUSSION: Contrast-enhanced T1-weighted MT-FLASH images improve lesion detection and delineation in the planning process of radiosurgery in patients with intracranial high grade gliomas or metastases and may even alter the treatment approach.

Entities:  

Mesh:

Year:  1997        PMID: 9215785     DOI: 10.1016/s0167-8140(97)00068-6

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  3 in total

1.  MRI assessment of experimental gliomas using 17.6 T.

Authors:  Marc A Schwarz; Mirko Pham; Xavier Helluy; Arnd Doerfler; Tobias Engelhorn
Journal:  Neuroradiology       Date:  2013-03-10       Impact factor: 2.804

2.  Amide proton transfer imaging of 9L gliosarcoma and human glioblastoma xenografts.

Authors:  Amandeep Salhotra; Bachchu Lal; John Laterra; Phillip Zhe Sun; Peter C M van Zijl; Jinyuan Zhou
Journal:  NMR Biomed       Date:  2008-06       Impact factor: 4.044

3.  Systematisation of spatial uncertainties for comparison between a MR and a CT-based radiotherapy workflow for prostate treatments.

Authors:  Tufve Nyholm; Morgan Nyberg; Magnus G Karlsson; Mikael Karlsson
Journal:  Radiat Oncol       Date:  2009-11-17       Impact factor: 3.481

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.